NEOLEUKIN THERAPEUTICS INC (NLTX) Stock Analyst Ratings
NASDAQ:NLTX - Nasdaq - US64049K2033 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 43% to NLTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.53. This target is -56.16% below the current price.
NLTX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about NLTX.
In the previous month the buy percentage consensus was at a similar level.
NLTX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-05-09 | Mizuho | Maintains | Neutral |
| 2023-01-03 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-11-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-11-15 | Mizuho | Downgrade | Buy -> Neutral |
| 2022-11-15 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-11-15 | Stifel | Downgrade | Buy -> Hold |
| 2022-11-15 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-09-12 | B of A Securities | Downgrade | Buy -> Underperform |
| 2022-09-12 | HC Wainwright & Co. | Maintains | Buy |
| 2022-03-02 | Piper Sandler | Maintains | Overweight |